Tumorigenesis News and Research

RSS

Tumorigenesis is the process involved in the production of a new tumor or tumors.

Molecular mechanisms regulating tumour initiation in skin SCC uncovered

Advanced online publication in Nature: Researchers at the Université libre de Bruxelles, ULB uncover the molecular mechanisms regulating tumour initiation and cancer stem cells functions in skin squamous cell carcinoma.

11 Jun 2014

Ezyme used as target for antidepressants may also provide way to cure prostate cancer

An international team of scientists including researchers at the Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute and the University of Southern California found that an enzyme commonly used as a target for antidepressants may also promote prostate cancer growth.

2 Jun 2014

Biologists show bioelectrical signals control tumors arising from cancer-causing genes, fatty acid

Developmental biologists at Tufts University, using a tadpole model, have shown that bioelectrical signals from distant cells control the incidence of tumors arising from cancer-causing genes and that this process is impacted by levels of a common fatty acid produced by bacteria found in the tadpole and also in humans.

28 May 2014

TSRI researchers discover key proteins involved in one type of DNA repair gone awry

Accumulation of DNA damage can cause aggressive forms of cancer and accelerated aging, so the body's DNA repair mechanisms are normally key to good health. However, in some diseases the DNA repair machinery can become harmful.

23 May 2014

Researchers discover key proteins involved in DNA repair gone awry

22 May 2014

TAG-1 induces apoptosis-related gene expression without triggering apoptosis in glioma cells

A recent study reported by Haigang Chang and co-workers from the First Affiliated Hospital of Xinxiang Medical University in China verified the effects of transient axonal glycoprotein-1 (TAG-1) on cell viability and p53, epidermal growth factor receptor (EGFR), and amyloid precursor protein (APP) intracellular C-terminal domain (AICD) expression in U251 glioma cells.

8 May 2014

BeiGene receives $5M from Merck to develop BGB-283 BRAF inhibitor

BeiGene (Beijing), Co., Ltd., an innovative oncology company focused on developing targeted and immune-oncology therapeutics, today announced the achievement of a clinical milestone in the company's collaboration with Merck Serono, the biopharmaceutical division of Merck, Darmstadt, Germany, for BGB-283, a second-generation BRAF inhibitor candidate currently in Phase 1 development.

6 May 2014

iQBS researchers develop new gene expression analysis approach for identifying cancer genes

Dartmouth Institute for Quantitative Biomedical Sciences (iQBS) researchers developed a new gene expression analysis approach for identifying cancer genes.

5 May 2014

AGA Research Foundation announces 2014 AGA Research Scholars

The American Gastroenterological Association Research Foundation is pleased to announce the 2014 AGA Research Scholars. The AGA Research Scholar Awards program, launched in 1984, enables young investigators to develop independent and productive research careers in digestive diseases. This year, the AGA Research Scholar Awards fund an additional year allowing for three consecutive years of funding.

25 Apr 2014

New genetic evidence strengthens link between role of dietary fats with colon cancer progression

Scientists have shown new genetic evidence that could strengthen the link between the role of dietary fats with colon cancer progression.

22 Apr 2014

Stanford researchers identify normal cell type that gives rise to most invasive bladder cancers

A single type of cell in the lining of the bladder is responsible for most cases of invasive bladder cancer, according to researchers at the Stanford University School of Medicine.

21 Apr 2014

Researchers discover hotspot L205R mutation is closely associated with adrenocortical tumors

Chinese researchers from Rui-Jin Hospital, Shanghai Jiao-Tong University School of Medicine, BGI, and other institutions have discovered that the activating hotspot L205R mutation in PRKACA gene was closely associated with adrenocortical tumors (ACTs), and the relationship of recurrently mutated DOT1L and CLASP2 with ACTs' other subtypes.

7 Apr 2014

Too little or too much of SRPK1 enzyme promotes cancer, shows research

Researchers at the University of California, San Diego School of Medicine have found that too little or too much of an enzyme called SRPK1 promotes cancer by disrupting a regulatory event critical for many fundamental cellular processes, including proliferation.

4 Apr 2014

IRB researchers identify dual role of p38 protein in colon cancer

A team headed by Angel R. Nebreda at the Institute for Research in Biomedicine identifies a dual role of the p38 protein in colon cancer. The study demonstrates that, on the one hand, p38 is important for the optimal maintenance of the epithelial barrier that protects the intestine against toxic agents, thus contributing to decreased tumour development.

28 Mar 2014

Novel feedback provides mechanistic link between chronic inflammation and carcinogenesis

Researchers of Ludwig-Maximilians-Universitaet (LMU) in Munich have discovered a novel feedback mechanism that provides a mechanistic link between chronic inflammation and carcinogenesis.

20 Mar 2014

Research reveals 2 key mechanisms of oxidative stress regulation

Regulation of oxidative stress is critical to cell survival. New preclinical research from Roswell Park Cancer Institute (RPCI) has revealed two key mechanisms by which oxidative stress is regulated in normal and cancerous cells.

7 Mar 2014

Scientists identify twenty proteins specifically secreted by primary effusion lymphoma cell lines

Primary effusion lymphoma (PEL) is a rare B-cell neoplasm distinguished by its tendency to spread along the thin serous membranes that line body cavities without infiltrating or destroying nearby tissue.

10 Feb 2014

Erythropoietin may promote cancer cell proliferation and survival

In recent years, non-hematopoietic effects of erythropoietin (EPO), via its binding to the EPO receptor in non-hematopoietic tissues, including cancerous tissues, has been reported by many different laboratories worldwide.

7 Jan 2014

BeiGene doses first patient in Phase 1 study of BGB-283

BeiGene (Beijing), Co., Ltd., today announced dose administration for the first patient in a Phase 1 study of BGB-283 in patients with B-RAF or K-RAS mutations. BGB-283 is an investigational, oral, selective, potent second generation inhibitor of B-RAF, making it a targeted therapeutic candidate to potentially treat and bring benefit to patients with cancers that harbor BRAF mutations and/or aberrations in the RAS-MAPK (mitogen-activated protein kinase) pathway.

20 Dec 2013

Circulating nucleosomes and colorectal cancer diagnostics: an interview with Dr. Stefan Holdenrieder, University Hospital Bonn

For my MD thesis I modified and evaluated an immunological assay that detected the cell death products “nucleosomes” as a new blood-based cancer biomarker. As cell death processes are enhanced or suppressed during different stages of tumor development, it was assumed that they may enable stage-dependent detection of cancer disease.

12 Dec 2013